JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer

Phase 1

Terminated

Conditions: Advanced Cancer

Interventions: Drug: JNJ-61610588

First Posted Date: 2016-02-02

Last Posted Date: 2018-03-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 12

Registration Number: NCT02671955

A Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-54416076 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-54416076
Drug: Placebo

First Posted Date: 2016-02-01

Last Posted Date: 2018-03-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 64

Registration Number: NCT02670395

Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort

Completed

Conditions: Autism Spectrum Disorder

First Posted Date: 2016-01-29

Last Posted Date: 2016-12-19

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 186

Registration Number: NCT02668991

A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-42847922
Drug: Rifampin

First Posted Date: 2016-01-25

Last Posted Date: 2016-05-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 14

Registration Number: NCT02661893

A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

Phase 1

Completed

Conditions: Influenza A Virus

Interventions: Drug: JNJ-63623872 300 milligram (mg)
Drug: JNJ-63623872 600 mg

First Posted Date: 2016-01-20

Last Posted Date: 2016-07-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 90

Registration Number: NCT02659735

A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy

Phase 2

Completed

Conditions: Visual Acuity
Geographic Atrophy
Macular Degeneration

Interventions: Drug: CNTO 2476 3.0 x 10^5 cells
Device: Subretinal Delivery System

First Posted Date: 2016-01-20

Last Posted Date: 2020-06-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 21

Registration Number: NCT02659098

A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-63623872 3000 mg
Drug: JNJ-63623872
Drug: JNJ-63623872 2400 milligram (mg)
Drug: Placebo (Matching with JNJ-63623872 2400 mg)
Drug: Placebo (Matching with JNJ-63623872 3000 mg)
Drug: Moxifloxacin
Drug: Placebo (Matching with JNJ-63623872 Dose)
Drug: Placebo (Matching with Moxifloxacin)

First Posted Date: 2016-01-20

Last Posted Date: 2016-06-17

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 66

Registration Number: NCT02658825

A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ethinylestradiol
Drug: Norethindrone
Drug: JNJ-63623872

First Posted Date: 2016-01-12

Last Posted Date: 2016-06-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18

Registration Number: NCT02652650

A Study in a Human Laboratory Model of Smoking Behavior

Phase 2

Completed

Conditions: Smoking

Interventions: Drug: CERC-501
Drug: Placebo

First Posted Date: 2015-12-29

Last Posted Date: 2024-12-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 71

Registration Number: NCT02641028

Locations: 🇺🇸
Vince and Associates, Overland Park, Kansas, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸
Columbia University, New York, New York, United States

A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ibrutinib
Drug: Omeprazole

First Posted Date: 2015-12-22

Last Posted Date: 2016-04-15

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 20

Registration Number: NCT02638116

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy